JPRN-UMIN000008507已完成2 期
A Phase II trial of DA-EPOCH And Rituximab with HD-MTX therapy for newly-diagnosed DLBCL with CD5 expression (PEARL5 study) - A Phase II trial of DA-EPOCH And Rituximab with HD-MTX therapy for newly-diagnosed DLBCL with CD5 expression (PEARL5 study)
CD5+ DLBCL Treatment Study Group0 个研究点目标入组 47 人开始时间: 2012年7月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) History of angle-closure glaucoma (2) Uncontrollable diabetes mellitus in spite of insulin therapy (3) Uncontrollable hypertension (4) Pleural effusion or ascites except for those with little amount (5) Coronary artery disease under treatment; cardiomyopathy, heart failure, or arrhythmia treated with anti-arrhythmic (6) HBs antigen positive (7) HCV antibody positive (8) HIV antibody positive (9) Interstitial pneumonia, pulmonary fibrosis (10) Severe infection (11) Liver cirrhosis (12) Other active malignancies; history of lymphoma, myelodysplastic syndrome, or leukemia (13) Pregnant, possible pregnant, or breastfeeding woman (14) Severe psychosis (15) Under systemic corticosteroid therapy (16) Considered as ineligible by attending physicians for other reasons
研究者
相似试验
已完成
2 期
PEARL5 studyJPRN-jRCTs041180159Yamaguchi Motoko45
已完成
2 期
A Phase II trial of Dose adjusted EPOCH and Rituximab therapy for newly-diagnosed DLBCL with C-MYC rearrangementC-MYC positive diffuse large B-cell lymphomaJPRN-UMIN000015972Kanagawa Clinical Oncology study Group34
进行中（未招募）
1 期
Phase II study of mini CHOP plus Rituximab in non previously treated patient aged over 80 years with CD20+ Diffuse Large B-cell Lymphoma - LNH03-7BCD20+ diffuse large B-cell lymphomaEUCTR2007-001589-34-BEGELA Group150
已完成
2 期
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40
已完成
2 期
A phase2 study of Rituximab+THP-COP(R-THP-COP) in elderly subjects with untreated, advanced, CD20-positive, indolent B-cell Non-Hodgkin's lymphomaindolent B-cell lymphomaJPRN-UMIN000002287Hematological Malignancy Clinical Study Group40